Lucid Diagnostics (LUCD) Debt Ratio (2021)
Lucid Diagnostics (LUCD) posted Debt Ratio of 6.8 for Q3 2021.
Lucid Diagnostics (LUCD) Debt Ratio (2021) Analysis & Trends
Lucid Diagnostics' Debt Ratio history runs 1 years deep, the most recent figure standing at 6.8 for Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 0.31 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 0.32 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 0.30 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 0.25 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 0.04 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 0.30 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 0.27 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 0.30 |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 6.80 |